| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adverse selection and consumer inertia: empirical evidence from the Dutch health insurance market
|
Croes, Ramsis R.
|
|
|
26 |
4 |
p. 641-651
|
artikel
|
| 2 |
Assessing a decade of leukaemia-related premature mortality costs: impact on productivity loss in Spain
|
Darbà, Josep
|
|
|
26 |
4 |
p. 619-625
|
artikel
|
| 3 |
Benefits beyond health in the willingness to pay for a quality-adjusted life-year
|
de Vries, Linda M.
|
|
|
26 |
4 |
p. 653-670
|
artikel
|
| 4 |
Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases
|
Szabó, Ákos
|
|
|
26 |
4 |
p. 627-639
|
artikel
|
| 5 |
Comparing the measurement properties of the EQ-5D-5 L, SF-6Dv2, QLU-C10D and FACT-8D among survivors of classical Hodgkin’s lymphoma
|
Xu, Richard Huan
|
|
|
26 |
4 |
p. 671-682
|
artikel
|
| 6 |
Comparison of four approaches in eliciting health state utilities with SF-6Dv2
|
Ameri, Hosein
|
|
|
26 |
4 |
p. 589-604
|
artikel
|
| 7 |
Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports
|
Li, Yan
|
|
|
26 |
4 |
p. 577-588
|
artikel
|
| 8 |
Does implementing opt-out solve the organ shortage problem? Evidence from a synthetic control approach
|
Schulze Spuentrup, Selina
|
|
|
26 |
4 |
p. 541-560
|
artikel
|
| 9 |
Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
|
Manders, Evert A.
|
|
|
26 |
4 |
p. 683-696
|
artikel
|
| 10 |
Pricing combination products: not how but who?
|
Towse, Adrian
|
|
|
26 |
4 |
p. 537-540
|
artikel
|
| 11 |
Strategic behavior and entry deterrence by branded drug firms: the case of authorized generic drugs
|
Yao, Lu
|
|
|
26 |
4 |
p. 561-575
|
artikel
|
| 12 |
The societal cost of ‘unwanted’ loneliness in Spain
|
Casal, Bruno
|
|
|
26 |
4 |
p. 605-617
|
artikel
|
Tijdschrift beschrijving